Please ensure Javascript is enabled for purposes of website accessibility

Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes

By Eric Volkman - May 5, 2021 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The developer of cannabis-based medications is now under new ownership.

Jazz Pharmaceuticals (JAZZ 1.83%) and GW Pharmaceuticals are now under the same corporate roof. The two companies announced Wednesday that Jazz's acquisition of GW has been completed. This brings the $7.6 billion cash-and-stock deal, first announced in early February, to a close.

In the companies' joint press release, Jazz CEO Bruce Cozadd was quoted as saying that the closing "mark[s] a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint."

US currency in the shape of a marijuana leaf.

Image source: Getty Images.

"The addition of GW further diversifies our commercial portfolio and innovative pipeline with therapies that are complementary to our existing business," he added.

A key attraction for Jazz is GW's Epidiolex, a cannabis-based medication that treats certain rare types of childhood-onset epilepsy. As its new owner is fond of saying, Epidiolex is a potential blockbuster drug. If it maintains its impressive growth trajectory (its sales increased 72% year over year in 2020), it could be a major revenue generator for Jazz.

In the press release, the two companies added that the absorption of GW should deliver "accelerated" double-digit revenue improvement for the combined entity, and be accretive in the first full calendar year as a single entity, although they did not provide specifics. Some are apparently forthcoming; Jazz and GW said that updated 2021 guidance will be proffered within 45 days.

Jazz investors seem to be expecting good numbers from their suddenly larger company. On Wednesday, the stock closed 6.6% higher, notably eclipsing the generally flat performance of the S&P 500 index on the day.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
JAZZ
$157.08 (1.83%) $2.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.